Switching to DrugPatentWatch
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch […]
Switching to DrugPatentWatch Read Post »
Insights
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Finding Hidden Treasures in Old Drugs: The Challenges and Importance of Licensing Generics
I. Executive Summary The pursuit of novel therapeutic options is a cornerstone of pharmaceutical research. However, a parallel and increasingly
Drug Repurposing: The Definitive Strategic Guide
A technically dense, data-grounded analysis of repurposing economics, IP valuation, regulatory pathways, computational platforms, and lifecycle management tactics for existing
Drug Repurposing: The Definitive Strategic Guide Read Post »
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model
Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
Generic Drug Launch Timing: The Complete Analyst’s Playbook for Predicting When Approved Generics Actually Hit the Market
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Chemical Databases in Drug Discovery: The Complete IP and R&D Intelligence Playbook
Introduction: The $2 Billion Data Problem Start with the math. A new drug costs roughly $2 billion and a decade
Chemical Databases in Drug Discovery: The Complete IP and R&D Intelligence Playbook Read Post »
Off-Label Drugs and Repurposing: The Full IP, Regulatory, and Commercial Playbook
The complete guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on extracting maximum asset value from
Off-Label Drugs and Repurposing: The Full IP, Regulatory, and Commercial Playbook Read Post »
